FDA Approves Expanded Indication for AJOVY® (fremanezumab-vfrm), The First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults1
This approval marks an important step in expanding the impact of AJOVY beyond adults since its U.S. approval in 2018, and underscores Teva's ongoing efforts to advance and address neurological challenges2
PARSIPPANY, N.J. and TEL AVIV, Israel, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today that the U.S. Food and Drug Administration (FDA) has approved AJOVY for the preventive treatment of episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. With this approval, AJOVY becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of episodic migraine in pediatric patients and migraine in adults, marking a meaningful advancement in expanding preventive treatment options for those living with migraine.
Preventative treatment can help reduce the frequency of migraine attacks, helping children and adolescents to better manage the condition day-to-day. AJOVY is administered once a month and available for in-office or at home use, offering a treatment option that is intended to support adherence and reduce treatment burden for families.1
'Migraines are a common yet invisible condition that can severely disrupt daily life for children and adolescents, often leaving them overlooked and misunderstood,' said Chris Fox, Executive Vice President, U.S. Commercial and Innovative Franchise Lead and Head of Global Marketing Business at Teva. 'With this FDA approval, AJOVY now offers younger patients a new treatment option, addressing a long-standing gap in care and offering families added support as they navigate the challenges of this condition.'
1 in 10 children and adolescents in the U.S. suffer from migraine, one of the most common and disabling neurological conditions.3 Despite its widespread prevalence, pediatric migraine is often underrecognized and undertreated, contributing to missed school days, difficulties with schoolwork, and disrupted social activities.4
"Pediatric migraine is a complex condition that can significantly impact a child's daily life, from school performance to emotional well-being," said Dr. Jennifer McVige, MD, MA, Pediatric Neurologist at the DENT Neurologic Institute. 'Having an FDA-approved treatment like AJOVY offers an important option, providing a targeted approach to preventive treatment for episodic migraine that can help reduce the frequency of attacks in younger patients and help clinicians manage this often-overlooked condition.'
Building on its established success in adult patients since its U.S. approval in 2018, this expanded indication strengthens Teva's commitment to broadening access to neuroscience therapies across age groups.2 AJOVY continues to demonstrate efficacy in addressing the underlying biology of migraine and now provides a treatment pathway for a patient population with historically limited preventive options.
About MigraineMigraine attacks cause disabling pain, nausea, vomiting and sensitivities to light and sound, resulting in serious effects on the ability to complete daily tasks.5 Migraine can cause significant disability in children and adolescents, leading to absence from school, impaired educational performance and missed social activities.3
About AJOVYAJOVY is indicated for preventive treatment of migraine in adults and episodic migraine in children and adolescent patients aged 6-17 years who weigh 45 kilograms (99 pounds) or more. AJOVY is available as a 225 mg/1.5 mL single dose injection in a pre-filled autoinjector or in a pre-filled syringe. AJOVY can be administered either by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. For full prescribing information, visit https://www.ajovy.com/globalassets/ajovy/ajovy-pi.pdf
INDICATION AND USAGE
AJOVY is indicated for:
the preventive treatment of migraine in adults, and
the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.
IMPORTANT SAFETY INFORMATION
Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. Cases of anaphylaxis and angioedema have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.
Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including AJOVY, in the postmarketing setting.
Monitor patients treated with AJOVY for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of AJOVY is warranted.
Raynaud's Phenomenon: Development of Raynaud's phenomenon and recurrence or worsening of pre-existing Raynaud's phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists, including AJOVY. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain.
AJOVY should be discontinued if signs or symptoms of Raynaud's phenomenon develop. Patients with a history of Raynaud's phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.
Adverse Reactions: The most common adverse reactions in clinical trials (≥5% and greater than placebo) were injection site reactions.
Please click here for full U.S. Prescribing Information for AJOVY (fremanezumab-vfrm) injection.
About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients' needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as 'should,' 'expect,' 'anticipate,' 'estimate,' 'target,' 'may,' 'project,' 'guidance,' 'intend,' 'plan,' 'believe' and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize AJOVY (fremanezumab) for the prevention of episodic migraine in children and adolescents; our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2025 and in our Annual Report on Form 10-K for the year ended December 31, 2024, including in the section captioned 'Risk Factors.' Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
AJOVY (fremanezumab-vfrm) injection, for subcutaneous use. Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc.
Data on file. Parsippany, NJ: Teva Neuroscience, Inc.
Al Khalili Y, Asuncion RMD, Chopra P. Migraine Headache in Childhood. [Updated 2023 Mar 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557813/
Pediatric Migraine, An Update. Greene, Kaitlin. et al; Neurology clinics, Volume 37, Issue 4, 815-833. August 31, 2019. https://doi.org/10.1016/j.ncl.2019.07.009
Jaimie D Steinmetz, Katrin Seeher, Nicoline Schiess, Emma Nichols, Bochen Cao, Chiara Servili, Vanessa Cavallera, Christopher J L Murray, Kanyin Liane Ong, Valery L Feigin, Theo Vos, and Tarun Dua on behalf of the GBD network. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Neurol. (in press).
Teva Media Inquiries:TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations InquiresTevaIR@Tevapharm.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August
Key Points Merck is an industry giant that has proved time and again it can innovate for the future. Ventas has positioned itself to grow its business and its dividend. Omega Healthcare Investors has survived the storm, and now it is ready to ride the wave. 10 stocks we like better than Merck › If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge risks. Three solid options that you might want to buy hand over fist right now are Merck (NYSE: MRK), Ventas (NYSE: VTR), and Omega Healthcare Investors (NYSE: OHI). Here's a primer on each one. 1. Merck is a high-yield survivor Merck's dividend yield is a pleasing 4.1% or so, more than twice the healthcare sector's average. The company has increased its payout annually for 15 consecutive years. From this standpoint, it is an attractive dividend stock, but what about the business? Merck is one of the world's largest pharmaceutical companies. Discovering new drugs is hard work, and it usually doesn't happen in a linear fashion. Right now, investors appear concerned that Merck's current patents will expire before it finds a new blockbuster to replace its older drugs. That's not unreasonable, since it is highly reliant on the revenue of just one drug right now (oncology treatment Keytruda). But this isn't an unusual development; it is kind of normal for drug companies to go through periods like this. What's important to note is that Merck's strong research and development capabilities and its scale (it can fairly easily buy smaller companies to bolster its drug pipeline if it needs to) have allowed it to thrive over the long term. And that has allowed the dividend to trend reliably higher for decades, though it has not increased every single year. If you can handle buying while others are selling, Merck looks like an attractive choice right now. Its yield is near the highest levels since the Great Recession. 2. Ventas cut its dividend, but now it's set to grow Ventas is a real estate investment trust (REIT) specializing in senior housing, with a dividend yield of 2.8%. That's not bad, but it's not exactly an earth-shattering figure. And on top of that, the REIT cut its dividend during the pandemic. It was the right move, given that senior housing facilities were particularly hard hit during that time. And the dividend cut allowed Ventas to work with its tenants and shift its business approach in a more growth-focused direction. Specifically, Ventas increased its exposure to properties that it both owns and operates (technically, it hires a property manager). This allows the revenue and costs to flow directly onto the income statement. When times are tough, like during the pandemic, that's bad news. When times are flush, however, these assets can supercharge earnings. Senior housing has come back strongly from the pandemic hit. And the aging demographics of the country suggest there's more growth to come. The big story, however, is that dividend increases have resumed. And given the growth-focused nature of the business right now -- adjusted funds from operations rose a heady 9% year over year in the second quarter -- it is reasonable to expect dividend raises to be quite attractive in the years ahead. 3. Omega Healthcare Investors is still out of favor Omega Healthcare's dividend yield is a lofty 6.7%. The payout hasn't been increased in years, but it also hasn't been cut. Like Ventas, Omega is a REIT that owns senior housing properties, and they were hard hit during the pandemic. Omega chose to hold the line on its dividend as it worked with its tenants. The portfolio repositioning has been difficult, but now that the world has mostly moved past the pandemic, things are starting to improve. Adjusted FFO rose around 8% in the second quarter. That strong showing isn't quite as big an opportunity on the dividend front here, however, because its payout remained high throughout the pandemic period. But it is a sign that Omega's payout is likely sustainable as it gets back on the growth track, including buying new properties. Ventas' exposure to senior housing and the graying of the country are growth engines. Omega's exposure to this same thing is a recovery engine. If you need income today, buying into its turnaround story will probably be more attractive to you than buying Ventas. Three solid dividend choices in the healthcare sector Even when the average healthcare stock has a miserly 1.8% yield, you can still find very attractive income options. Merck is a tried-and-true dividend payer with a well-run business and attractive yield. Ventas, which also has an attractive yield, repositioned itself for growth during the pandemic, and that is now starting to shine through on the dividend side of things. And Omega muddled through the pandemic without a dividend cut, leaving it with a high yield today and a strengthening business. August could be a great time to buy one or more of these healthcare dividend stocks. Should you buy stock in Merck right now? Before you buy stock in Merck, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Merck wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool has a disclosure policy. 3 High-Yield Healthcare Stocks to Buy Hand Over Fist in August was originally published by The Motley Fool
Yahoo
2 hours ago
- Yahoo
Wells Fargo Sticks with Overweight on UnitedHealth (UNH), Trims Target to $267
UnitedHealth Group Inc. (NYSE:UNH) is one of the best defensive stocks to invest in according to analysts. At the time of writing this article, UnitedHealth ranks among the 10 biggest year-to-date decliners, which have lost over 50% among U.S.-listed stocks with a market capitalization exceeding $2 billion. The company, which was marred by government investigations, operational failures, and leadership changes, reported mixed Q2 2025 earnings results at the end of July. Those results have been unable to shore up the share price, as the long-term growth outlook is still murky. A close-up of a healthcare professional studying a computer screen with data while consulting with a patient. The company guided for 2025 adjusted EPS to be over $16, which was significantly below Bloomberg's consensus expectations of $20.4. Seeing the brighter side, Jeff Jonas, portfolio manager at Gabelli Funds, called the guidance highly conservative and believes that it will be easier for the company to beat such low expectations. However, the steep correction and valuation discount have attracted analysts' interest, with around two-thirds of them having a Buy or equivalent rating. One of the analysts who maintains an optimistic view is Wells Fargo's Stephen Baxter. On August 4, Baxter maintained an Overweight rating on UnitedHealth but lowered his price target to $267 from $306. The revision followed a recently held management meeting where he assessed the company's updated outlook. According to the analyst, UnitedHealth's management remains confident in the company's ability to meet its reset 2025 guidance. In his view, management is taking a cautious but disciplined approach in factoring in cost trends and margin recovery. Baxter views this conservatism positively, suggesting it reduces the risk of further downside revisions. UnitedHealth Group Inc. (NYSE:UNH) is a healthcare company that provides health insurance and healthcare solutions in the U.S. and globally under the UnitedHealthcare and Optum brands. While we acknowledge the potential of UNH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Cigna (CI) Pullback a Buying Opportunity, Says TD Cowen with a Buy Rating
The Cigna Group (NYSE:CI) is one of the best defensive stocks to invest in according to analysts. Cigna shares cracked over 10% on July 31 after the company reported its Q2 2025 quarterly results. Following the results, TD Cowen analyst Charles Rhyee reiterated a Buy rating on Cigna, maintaining a $387 price target. He believes the recent pullback in the shares was overdone and sees current levels as an attractive entry point. A health care professional consulting with patients in a state-of-the-art facility. While concerns around performance in the Health Insurance Exchange (HIX) segment weighed on sentiment, Rhyee expects the impact to be limited. He points to strength in other parts of the business, particularly Specialty and Care Services, as well as solid momentum in the company's Pharmacy Benefit Management (PBM) operations, which should help offset pressures. Rhyee also noted that management's Q3 guidance appears cautious, especially considering stepped-up investment in improving patient experience. Still, he remains confident in the company's earnings outlook, with robust EPS growth projections for 2025 and 2026 supporting his valuation. The Cigna Group (NYSE:CI) is a health services company that provides medical, pharmacy, behavioural health, dental, and supplemental insurance products. While we acknowledge the potential of CI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Most Oversold S&P 500 Stocks So Far in 2025 and 10 Most Oversold Semiconductor Stocks So Far in 2025. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
